et140202 autologous t cell product
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 30, 2019 (NCT03998033)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Tumor antigensImmunity, passive
immunity, passive - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03965546 | Early Phase 1 (Phase 1) | Jun 30, 2019 | Aeon Therapeutics (Shanghai) Co., Ltd., Jiao Tong University |
| NCT03998033 | Phase 1/Phase 2 (Phase 2) | May 30, 2019 | Aeon Therapeutics (Shanghai) Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aeon Therapeutics (Shanghai) Co., Ltd. | For profit | 2 | 1 | 2 | 2019 |
| Jiao Tong University | Academic/Hospital | 1 | 1 | 1 | 2019 |
2 organizations
Page 1 / 1